Cyclacel Pharmaceuticals Historical PE Ratio image   This CYCC PE ratio history page last updated 11/10/2022
Cyclacel Pharmaceuticals Historical PE Ratio Chart
PeriodPriceGAAPAnnualizedPE
Q3 2022
11/9/2022
1.18-0.42-1.68NA
Q2 2022
8/10/2022
1.33-0.46-1.84NA
Q1 2022
5/11/2022
1.32-0.42-1.68NA
Q4 2021
3/28/2022
3.15-0.54-2.16NA
Q3 2021
11/10/2021
5.10-0.54-2.16NA
Q2 2021
8/11/2021
5.22-0.56-2.24NA
Q1 2021
5/12/2021
6.37-0.50-2.00NA
Q4 2020
2/25/2021
7.00-1.34-5.36NA
Q3 2020
11/11/2020
3.51-0.47-1.88NA
Q2 2020
8/12/2020
4.56-0.58-2.32NA
Q1 2020
5/12/2020
4.13-1.48-5.92NA
Q4 2019
2/26/2020
12.20-2.80-11.20NA
Q3 2019
11/13/2019
7.60-2.20-8.80NA
Q2 2019
8/13/2019
9.00-2.20-8.80NA
Q1 2019
5/14/2019
13.80-2.80-11.20NA
Q4 2018
3/27/2019
18.00-3.40-13.60NA
Q3 2018
11/12/2018
24.20-3.60-14.40NA
Q2 2018
8/9/2018
31.20-3.20-12.80NA
Q1 2018
5/14/2018
28.60-2.40-9.60NA
Q4 2017
3/28/2018
26.602.208.803.0
Q3 2017
11/9/2017
33.00-3.80-15.20NA
Q2 2017
8/9/2017
33.80-10.00-40.00NA
Q1 2017
5/11/2017
106.00-7.60-30.40NA
Q4 2016
3/28/2017
73.20-13.80-55.20NA
Q3 2016
11/14/2016
78.20-17.20-68.80NA
Q2 2016
8/10/2016
95.80-20.20-80.80NA
Q1 2016
5/11/2016
88.80-21.60-86.40NA
Q4 2015
3/24/2016
103.20-24.00-96.00NA
Q3 2015
11/12/2015
136.80-19.20-76.80NA
Q2 2015
8/11/2015
134.40-24.00-96.00NA
Q1 2015
5/12/2015
184.80-45.60-182.40NA
Q4 2014
3/24/2015
230.40-50.40-201.60NA
Q3 2014
11/11/2014
744.00-52.80-211.20NA
Q2 2014
8/12/2014
777.60-52.80-211.20NA
Q1 2014
5/13/2014
758.40-60.00-240.00NA
Q4 2013
3/25/2014
878.40-45.60-182.40NA
Q3 2013
11/12/2013
960.00-76.80-307.20NA
Q2 2013
8/14/2013
703.2024.0096.007.3
Q1 2013
5/13/2013
924.00-283.20-1132.80NA
Q4 2012
3/27/2013
1339.20-141.60-566.40NA
Cyclacel Pharmaceuticals PE History Chart
PeriodPriceGAAPTTMPE
Q3 2022
11/9/2022
1.18-0.42-1.84NA
Q2 2022
8/10/2022
1.33-0.46-1.96NA
Q1 2022
5/11/2022
1.32-0.42-2.06NA
Q4 2021
3/28/2022
3.15-0.54-2.14NA
Q3 2021
11/10/2021
5.10-0.54-2.94NA
Q2 2021
8/11/2021
5.22-0.56-2.87NA
Q1 2021
5/12/2021
6.37-0.50-2.89NA
Q4 2020
2/25/2021
7.00-1.34-3.87NA
Q3 2020
11/11/2020
3.51-0.47-5.33NA
Q2 2020
8/12/2020
4.56-0.58-7.06NA
Q1 2020
5/12/2020
4.13-1.48-8.68NA
Q4 2019
2/26/2020
12.20-2.80-10.00NA
Q3 2019
11/13/2019
7.60-2.20-10.60NA
Q2 2019
8/13/2019
9.00-2.20-12.00NA
Q1 2019
5/14/2019
13.80-2.80-13.00NA
Q4 2018
3/27/2019
18.00-3.40-12.60NA
Q3 2018
11/12/2018
24.20-3.60-7.00NA
Q2 2018
8/9/2018
31.20-3.20-7.20NA
Q1 2018
5/14/2018
28.60-2.40-14.00NA
Q4 2017
3/28/2018
26.602.20-19.20NA
Q3 2017
11/9/2017
33.00-3.80-35.20NA
Q2 2017
8/9/2017
33.80-10.00-48.60NA
Q1 2017
5/11/2017
106.00-7.60-58.80NA
Q4 2016
3/28/2017
73.20-13.80-72.80NA
Q3 2016
11/14/2016
78.20-17.20-83.00NA
Q2 2016
8/10/2016
95.80-20.20-85.00NA
Q1 2016
5/11/2016
88.80-21.60-88.80NA
Q4 2015
3/24/2016
103.20-24.00-112.80NA
Q3 2015
11/12/2015
136.80-19.20-139.20NA
Q2 2015
8/11/2015
134.40-24.00-172.80NA
Q1 2015
5/12/2015
184.80-45.60-201.60NA
Q4 2014
3/24/2015
230.40-50.40-216.00NA
Q3 2014
11/11/2014
744.00-52.80-211.20NA
Q2 2014
8/12/2014
777.60-52.80-235.20NA
Q1 2014
5/13/2014
758.40-60.00-158.40NA
Q4 2013
3/25/2014
878.40-45.60-381.60NA
Q3 2013
11/12/2013
960.00-76.80-477.60NA
Q2 2013
8/14/2013
703.2024.00NANA
Q1 2013
5/13/2013
924.00-283.20NANA
Q4 2012
3/27/2013
1339.20-141.60NANA
Quotes delayed 20 minutes

Email EnvelopeFree CYCC Email Alerts:
Get Dividend Alerts
Get SEC Filing Alerts
10 Most Oversold S&P 500 Stocks
10 Most Overbought S&P 500 Stocks
10 ETFs With Stocks Insiders Are Buying
10 ETFs With Most Upside To Targets
The DividendRank Top 25
Warren Buffett Dividend Stocks
10 Cheap Dividend Stocks Under $10
10 Top DividendRank'ed Energy Stocks
The 10 Highest Yielding Preferred Stocks
The 10 Highest Yielding Preferred Stocks
The 15 Most Active S&P Call & Put Options
Cyclacel Pharmaceuticals (CYCC) is categorized under the Healthcare sector; to help you further research PE history across stocks, below are some other companies in the same sector:

CYCN PE Ratio History
CYH PE Ratio History
CYRX PE Ratio History
CYT PE Ratio History
CYTH PE Ratio History
CYTK PE Ratio History
DARE PE Ratio History
DAWN PE Ratio History
DBTX PE Ratio History
DCPH PE Ratio History
How should the CYCC historical PE ratio be determined?
Realizing that PE stands for Price to Earnings ratio, we need two values to compute it: stock price and earnings per share. The stock price at any given date is a known historical value, but what about the earnings number to use?

✔️Accepted answer: There are a number of different approaches when it comes to calculating a historical PE ratio for a company like Cyclacel Pharmaceuticals. We like to take our measurements on each of the past quarterly earnings reports. That only leaves the question of whether the earnings number at that quarterly report should be used on an annualized basis, or some other method. We approach this question using three different methods, on this CYCC Historical PE Ratio page.

What is the average historical PE for CYCC based on annualized quarterly earnings?
As we look back through earnings history, what is the resulting PE calculation if at each measurement period we use that quarter's earnings result annualized?

✔️Accepted answer: The CYCC historical PE ratio using the annualized quarterly earnings method works out to 5.2.

What is the average historical PE for CYCC based on trailing twelve month earnings?
As we look back through earnings history, what is the resulting PE calculation if at each measurement period we use the trailing twelve months combined earnings result in the calculation?

✔️Accepted answer: The CYCC historical PE ratio using the TTM earnings method works out to NA.

On this page we presented the Cyclacel Pharmaceuticals Historical PE Ratio information for Cyclacel Pharmaceuticals' stock. The average CYCC historical PE based on using the annualized quarterly earnings result at each measurement period (for the "E" in the PE calculation; and the closing price on earnings date as the "P") is 5.2. Meanwhile, using the trailing twelve month (TTM) quarterly earnings result as our method of calculation the "E" value at each measurement period, the average CYCC historical PE based on this TTM earnings result method is NA. Note: any PE calculations involving negative earnings were discarded as not meaningful.

Let's now compare this CYCC historical PE result, against the recent PE: when this page was posted on 11/9/2022, the most recent closing price for CYCC had been 1.18, and the most recent quarterly earnings result, annualized, was 8.8. Meanwhile, the most recent TTM earnings summed to NA. From these numbers, we calculate the recent CYCC PE on 11/9/2022 based on annualized quarterly EPS was 0.1. Based on CYCC's history, that recent PE is low relative to the historical average, with the recent PE 98.1% lower than the historical average PE across our data set for Cyclacel Pharmaceuticals.

For self directed investors doing their due diligence on CYCC or any other given stock, valuation analysis for CYCC can greatly benefit from studying the past earnings and resulting PE calculations. This exercise can help inform an analysis as to whether the past earnings trajectory and current versus historical PE ratios justify the current stock value.

That's why we bring you HistoricalPERatio.com to make it easy for investors to investigate Cyclacel Pharmaceuticals PE history or the past PE information for any stock in our coverage universe. And in your continued research we hope you will be sure to check out the further links included for earnings surprises history (beat/miss data) as well as next earnings dates for CYCC. Thanks for visiting, and the next time you need to research CYCC Historical PE Ratio or the ratio for another stock, we hope you'll think of our site, as your go-to historical PE ratio research resource of choice.

Recommended: SMP market cap history, NRG Energy Historical PE Ratio, FRI Dividend History.

 

Cyclacel Pharmaceuticals Historical PE Ratio | www.HistoricalPERatio.com | Copyright © 2020 - 2022, All Rights Reserved

Nothing in HistoricalPERatio.com is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Use and Privacy Policy. Video widget and market videos powered by Market News Video. Quote and option data delayed at least 15 minutes; stock quote data powered by Ticker Technologies, and Mergent.